CSG Cloud-Native Rating and Charging Solution Now in Production With Customers Worldwide
29.4.2020 15:00:00 EEST | Business Wire | Press release
CSG ® (NASDAQ: CSGS) today introduced a new addition to its Ascendon platform, CSG Ascendon Rating & Charging, a fully cloud-native, serverless charging software as a service (SaaS). Now actively in use, the solution provides CSG customers with real-time online charging functionality and rating capabilities to support and scale for wireless and digital services offered today and in the future.
As device types and connections surge, operators need highly flexible solutions to rate and charge for events in real-time, at scale, and for innovative monetization models. As a fully hosted, multi-tenant, SaaS solution architected on Amazon Web Services (AWS), Ascendon Rating and Charging elastically scales when volumes fluctuate allowing for efficient and cost-effective management of network resources.
The solution can be used to configure any combination of products, offers, and eligibility rules, as well as how they are sold across channels, in a matter of minutes. It enables balance sharing across multiple devices and services and gives operators the ability to charge dynamically based on network events, with real-time notifications to help engage the customer.
The solution also provides online charging system (OCS) capabilities including real-time authorization and balance management for voice, data, content and digital services; usage processing and rating; and dynamic entitlements that ensure accurate charging.
“Modern business models are centered around emerging digital offers that can be deployed quickly and cost effectively,” said Chad Dunavant, head of global product management, CSG. “CSG Ascendon Rating and Charging is a new breed of cloud-native SaaS that helps operators successfully deploy new services like 5G, while helping them manage risk and optimize operational costs.” (video)
Key technical features include:
- Resiliency by design: High availability and geographically distributed across multiple AWS availability zones (AZs) to help ensure a fail-proof environment. It exceeds the resilience of traditional data centers by utilizing multiple AZs by design, providing a minimum of active-active-active configuration.
- Grow as you go: Provides an unlimited supply of cloud-compute and scalability through AWS, taking the guesswork out of required capacity and eliminating the need for large upfront capital expenditures, lowering operational costs.
- Fully featured and highly flexible: Configurable to support any wireless or digital service or bundled offer, as well as multiple charging models including pre-pay, post-pay, currency conversion, payments, invoicing, and adjustments.
- Fully managed: Complete management of operations and issues, as well as automated quarterly releases deployed by CSG, allowing for rapid deployment of new features and efficient management of resources internally.
- Network/platform agnostic: Charge for any transaction across any network or service platform.
This solution is part of CSG Ascendon, a globally recognized and award-winning digital monetization platform that has helped some of the world’s most innovative companies not just compete but thrive in the digital economy. Ascendon is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities that support more than 500 companies globally, providing them with flexible and configurable technology solutions that help them monetize and digitally enable their customer experiences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005067/en/
Contact information
Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com
David Banks
Investor Relations
CSG
+1 (303) 200-3127
david.banks@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
